A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

This trial tests a new drug called BPI-1178 in people with advanced solid tumors, with a focus on hormone receptor-positive, HER2-negative breast cancer that has come back or spread. The early phase tests safety in many cancer types; the later phase focuses specifically on breast cancer. **You may be eligible if...** - You are 18 or older - You have an advanced solid tumor that has stopped responding to standard treatment (Phase 1), OR - You have hormone receptor-positive, HER2-negative breast cancer that is locally advanced or metastatic (Phase 2) - You have not responded to previous therapies or have no good standard options left **You may NOT be eligible if...** - You have had too many prior chemotherapy treatments - You have serious medical conditions affecting organ function - Your cancer does not meet the specific type and stage criteria Talk to your doctor to see if this trial is right for you.